Home › NDC Lookup › RxCUI directory › RxCUI 2054086

5 ML mogamulizumab-kpkc 4 MG/ML Injection [Poteligeo] — RxCUI 2054086

RxNorm drug concept · Semantic branded drug
RxCUI 2054086 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2054086
Official name5 ML mogamulizumab-kpkc 4 MG/ML Injection [Poteligeo]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as5 ML Poteligeo 4 MG/ML Injection; POTELIGEO 20 MG in 5 ML Injection; Poteligeo 20 MG per 5 ML Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)230 prescriptions · 8 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mogamulizumab-kpkc Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Yes. Poteligeo treats two rare types of T-cell lymphoma — cancers that grow from a type of immune cell called a T-cell — that mainly show up in the skin. Mycosis fungoides (MF) cau...
  • What exactly is Poteligeo treating — is it a type of cancer?
  • Poteligeo is given as an IV infusion in a clinic or infusion center — a slow drip into your vein that takes at least an hour each time. In the first month, you'll come in four time...
  • How will I receive this medication, and how often do I need to come in?
📖 Read our full Mogamulizumab-kpkc Injection guide →

🕸️ Concept Web — How 5 ML mogamulizumab-kpkc 4 MG/ML Injection [Potel... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 5 ML mogamulizumab-kpkc 4 MG/ML Injection [Poteligeo] RxCUI 2054086

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Mogamulizumab 2054068
    • Mogamulizumab-kpkc 2054077
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Poteligeo 2054082
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mogamulizumab Injection 2054080
    • Mogamulizumab-kpkc Injection 2648159
    • Mogamulizumab Injectable Product 2054079
    • Mogamulizumab-kpkc Injectable Product 2661944
    • Mogamulizumab Injection [Poteligeo] 2054084
    • Mogamulizumab-kpkc Injection [Poteligeo] 2658694
    • Poteligeo Injectable Product 2054085
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 5 ML mogamulizumab-kpkc 4 MG/ML Injection SCD · 2054081
  • Mogamulizumab-kpkc 4 MG/ML SCDC · 2054078
  • Mogamulizumab Injection SCDF · 2054080
  • Mogamulizumab-kpkc Injection SCDFP · 2648159
  • Mogamulizumab Injectable Product SCDG · 2054079
  • Mogamulizumab-kpkc Injectable Product SCDGP · 2661944

Brand-Name Concepts

  • Mogamulizumab-kpkc 4 MG/ML [Poteligeo] SBDC · 2054083
  • Mogamulizumab Injection [Poteligeo] SBDF · 2054084
  • Mogamulizumab-kpkc Injection [Poteligeo] SBDFP · 2658694
  • Poteligeo Injectable Product SBDG · 2054085
  • Poteligeo BN · 2054082

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2054086 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
42747-0761-01 1 VIAL, GLASS in 1 CARTON (42747-761-01) / 5 mL in 1 VIAL,... POTELIGEO Kyowa Kirin, Inc. 2018-08-08
Observed labelers: Kyowa Kirin, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9204 Inj mogamulizumab-kpkc, 1 mg 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.